The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and ...

There appears to be growing frustration about FDA Commissioner Marty Makary’s management style within the highest levels of ...